CLINICAL_TRIALS trial_result · 2020-09-23

Clinical Trial Update: Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

Phase 2 safety and biomarker trial of EPI-589 in participants with amyotrophic lateral sclerosis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: PTC Therapeutics | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2020-09-23